Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients

F. G. Cosio, G. S. Giebink, C. T. Le, G. Schiffman

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Polyvalent pneumococcal vaccine was administered to 7 patients with chronic renal failure, 14 patients on chronic hemodialysis, 14 splenectomized and 11 nonsplenectomized renal allograft recipients, and 14 normal adults. Ninety-three percent of normal subjects had at least a twofold rise in serum antibody concentration after vaccination, with a geometric mean antibody concentration after vaccination greater than 200 ng N/ml. The response to vaccination in hemodialysis patients was similar to that in normal persons. Renal failure patients showed impaired antibody synthesis in response to the vaccine, with 43% achieving at least a twofold rise in antibody concentration. Allograft recipients had a lower antibody concentration before as well as after vaccination, and among splenectomized recipients the prevaccination antibody concentration was directly related to the interval between transplantation and antibody determination. But, 80% of allograft recipients achieved a twofold rise in antibody concentration after vaccination. The response to pneumococcal vaccine was quantitatively similar for splenectomized and nonsplenectomized allograft recipients.

Original languageEnglish (US)
Pages (from-to)254-258
Number of pages5
JournalKidney international
Issue number2
StatePublished - 1981

Bibliographical note

Funding Information:
This work was supported in part by contract NO1-AI-42541 from the National Institute of Allergy and Infectious Disease. We thank Dr. D. A. Duncan, C. M. Kjellstrand, J. S. Najarian, and R. L. Simmons for providing the patients, Miss C. Tollefson for secretarial assistance, and the Lederle Corporation, American Cyanamide, Pearl River, New York, for providing the pneumococcal vaccine used in this study.


Dive into the research topics of 'Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients'. Together they form a unique fingerprint.

Cite this